Sørensen A M, Christensen S, Jonassen T E, Andersen D, Petersen J S
Københavns Universitet, Panum Instituttet.
Ugeskr Laeger. 1998 Mar 2;160(10):1460-4.
Since the introduction of angiotensin converting enzyme-inhibitors (ACE-inhibitors) in the 1980's, more than 50 cases of foetotoxic effects ascribed to intrauterine exposure to inhibitors have been published. Among the most commonly reported effects are: Hypotension, renal dysplasia, anuria/oliguria, oligohydramios, intrauterine growth retardation, pulmonary hypoplasia, unclosed ductus arteriosus, incomplete ossification of the skull, intrauterine og neonatal death. Recent animal studies have confirmed that intrauterine or neonatal exposure to ACE-inhibitors or the AT1-receptor antagonist losartan can cause death and serious, irreversible organ damage. These effects are similar to the complications previously reported in humans. Animal studies suggest that the foetotoxic actions are most common after exposure during the last trimester. However, due to the severity of these complications, the use of ACE-inhibitors and AT1-receptor antagonists should be avoided throughout pregnancy and in women who are breast feeding.
自20世纪80年代引入血管紧张素转换酶抑制剂(ACE抑制剂)以来,已有超过50例因宫内接触该抑制剂而导致胎儿毒性作用的病例被报道。最常报告的影响包括:低血压、肾发育不全、无尿/少尿、羊水过少、宫内生长受限、肺发育不全、动脉导管未闭、颅骨骨化不全、宫内及新生儿死亡。最近的动物研究证实,宫内或新生儿接触ACE抑制剂或AT1受体拮抗剂氯沙坦可导致死亡和严重的、不可逆转的器官损害。这些影响与先前在人类中报道的并发症相似。动物研究表明,胎儿毒性作用在妊娠晚期接触后最为常见。然而,由于这些并发症的严重性,整个孕期以及哺乳期妇女应避免使用ACE抑制剂和AT1受体拮抗剂。